Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fezolinetant

fezolinetant

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of fezolinetant

5 trials tracked of fezolinetant: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 108 citations.

5Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 2
  1. Phase 3 A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause Completed · 108 cited
  2. Phase 3 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause Completed · 15 cited
  3. Phase 3 A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 Completed · 14 cited
  4. Phase 2 Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes Completed
  5. Phase 2 A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes) Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
In Silico Modeling Predicts Fezolinetant Hepatotoxicity Risk in MAFLD Population
Gastroenterology Phase II
In Silico Modeling Predicts Fezolinetant Hepatotoxicity Risk in MAFLD Population Could a menopause drug harm the liver? A computer model offers clues
Quantitative systems toxicology modeling simulated fezolinetant hepatotoxicity in virtual populations.
A computer model predicts a menopause drug might cause rare liver injury in people with fatty liver disease, but higher doses could be safer…
Apr 6, 2026